Non-surgical management of leiomyoma: impact on fertility

被引:61
作者
Olive, DL [1 ]
Lindheim, SR [1 ]
Pritts, EA [1 ]
机构
[1] Univ Wisconsin, Sch Med, Dept Obstet & Gynecol, Madison, WI 53706 USA
关键词
fibroids; treatment; infertility; medical; embolization;
D O I
10.1097/00001703-200406000-00006
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Purpose of review This review is designed to discuss the literature, published from December 2002 to January 2004, on the non-surgical treatment of fibroid. All established and new modalities are reviewed, and all new developments in the field are discussed. The resulting impact on the treatment of infertility will also be evaluated. Recent findings In the past year important advances occurred in the medical treatment of uterine fibroids. It was found, in a large randomized trial, that preoperative treatment with gonadotropin-releasing hormone analogue did not improve surgical results or decrease blood loss. However, important strides were made in understanding the molecular biology of the effect of the hormone analogue on fibroids. Other medical therapies investigated include danazol, raloxifene, mifepristone, aromatase inhibitors, and the levonorgestrel-containing intrauterine device. Most promising in terms of long-term usage for reduction of size and symptoms appears to be the combination of gonadotropin-releasing hormone analogue and raloxifene, although selective progesterone receptor modulators may also achieve this aim. However, none avoid producing an anovulatory state that inhibits fertility, and none have been shown to enhance fertility following discontinuation. Uterine artery embolization is another nonsurgical technique under intense investigation. The year's literature suggests that while results are comparable with hysterectomy in terms of complication rate and patient satisfaction, there may be important issues for women who wish to undergo the procedure and retain future fertility. Specifically, there is a significant rate of premature ovarian failure, as well as occasional damage to the endometrial vasculature with resulting atrophy and adhesion formation. Improvements in technique, in particular the use of larger and more spherical microspheres for embolization, may reduce these unwanted effects. However, few data exist regarding the course of pregnancy and outcome following embolization. Summary A number of non-surgical treatments exist for uterine fibroids, but none has been shown to be of value in the patient desiring future fertility. Myomectomy remains the standard of care for such women, and all other therapies should be designated experimental and limited to appropriate investigational studies.
引用
收藏
页码:239 / 243
页数:5
相关论文
共 35 条
  • [1] Effects of treatment with gonadotropin releasing hormone agonist on the uterine leiomyomata structure
    Bozzini, N
    Rodrigues, CJ
    Petti, DA
    Bevilacqua, RG
    Gonçalves, SP
    Pinotti, JA
    [J]. ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2003, 82 (04) : 330 - 334
  • [2] Laparoscopic myomectomy in premenopausal women with and without preoperative treatment using gonadotrophin-releasing hormone analogues
    Campo, S
    Garcea, N
    [J]. HUMAN REPRODUCTION, 1999, 14 (01) : 44 - 48
  • [3] Gene expression profile of leiomyoma and myometrium and the effect of gonadotropin releasing hormone analogue therapy
    Chegini, N
    Verala, J
    Luo, XP
    Xu, JX
    Williams, RS
    [J]. JOURNAL OF THE SOCIETY FOR GYNECOLOGIC INVESTIGATION, 2003, 10 (03) : 161 - 171
  • [4] Gonadotropin releasing hormone analogue therapy alters signal transduction pathways involving mitogen-activated protein and focal adhesion kinases in leiomyoma
    Chegini, N
    Kornberg, L
    [J]. JOURNAL OF THE SOCIETY FOR GYNECOLOGIC INVESTIGATION, 2003, 10 (01) : 21 - 26
  • [5] Effects of GnRH analogues, 'add-back' steroid therapy, antiestrogen and antiprogestins on leiomyoma and myometrial smooth muscle cell growth and transforming growth factor-β expression
    Chegini, N
    Ma, C
    Tang, XM
    Williams, RS
    [J]. MOLECULAR HUMAN REPRODUCTION, 2002, 8 (12) : 1071 - 1078
  • [6] Pathologic features of uteri and leiomyomas following uterine artery embolization for leiomyomas
    Colgan, TJ
    Pron, G
    Mocarski, EJM
    Bennett, JD
    Asch, MR
    Common, A
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2003, 27 (02) : 167 - 177
  • [7] A benefit-risk assessment of medical treatment for uterine leiomyomas
    De Leo, V
    Morgante, G
    La Marca, A
    Musacchio, MC
    Sorace, M
    Cavicchioli, C
    Petraglia, F
    [J]. DRUG SAFETY, 2002, 25 (11) : 759 - 779
  • [8] Short-term treatment of uterine fibromyomas with danazol
    De Leo, V
    la Marca, A
    Morgante, G
    [J]. GYNECOLOGIC AND OBSTETRIC INVESTIGATION, 1999, 47 (04) : 258 - 262
  • [9] Low-dose mifepristone for uterine leiomyomata
    Eisinger, SH
    Meldrum, S
    Fiscella, K
    le Roux, HD
    Guzick, DS
    [J]. OBSTETRICS AND GYNECOLOGY, 2003, 101 (02) : 243 - 250
  • [10] TREATMENT WITH GNRH AGONISTS BEFORE MYOMECTOMY AND THE RISK OF SHORT-TERM MYOMA RECURRENCE
    FEDELE, L
    VERCELLINI, P
    BIANCHI, S
    BRIOSCHI, D
    DORTA, M
    [J]. BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1990, 97 (05): : 393 - 396